Gastrointestinal Therapeutics Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2025 – 2034

Gastrointestinal Therapeutics Market Size

The global gastrointestinal therapeutics market generated significant revenues in 2024 and is poised to grow at a considerable CAGR during 2025-2034 driven by the increasing prevalence of gastrointestinal (GI) disorders, including Crohn's disease, irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and ulcerative colitis. A 2023 cross-sectional retrospective study conducted in the U.S. found that approximately 2.39 million Americans had been diagnosed with inflammatory bowel disease (IBD), including 1.25 million ulcerative colitis, and approximately 1.01 million Crohn's.
 

The increasing incidence of GI pathological complications is likely caused by various lifestyle changes, dietary practices, increased use of non-steroidal anti-inflammatory drugs (NSAIDs), decreased management of stress, etc. The booming older population with compromised GI tracts is providing further impetus for needed therapeutic solutions, as the aged population experiences more chronic gastrointestinal diseases than the younger populations.
 

Additionally, the situation holds for the market in the form of developing medicines through medical delivery systems, such as sustained-release tablets or oral biologics, which improves patient compliance and pharmaceutical manufacturers have also invested considerable amounts of time and money developing truly targeted therapies including monoclonal antibodies and small molecule inhibitors and ultimately attempts to improve the outcomes while mitigating adverse events. There will be even more growth for the market on a global scale with improved awareness and healthcare infrastructure in emerging economies. Ultimately, the industry will continue to have upward momentum with approvals of new drugs, improved clinical trial data, and new personalized therapies based on genomics in development, respectively.
 

Gastrointestinal Therapeutics Market Trends

There are several disruptive trends changing the direction of the market. One of the most prominent shifts is the increasing use of biologics and biosimilars as an option for patients with severe chronic manifestations of diseases like Crohn's and ulcerative colitis. Biologics and biosimilars provide targeted intervention with potentially less systemic function while offering the potential for long-term outcomes and benefits that are attractive to both clinicians and patients alike. Personalized medicine is also a major catalyst for change as genetic testing and biomarker identification become more widely available. You will hear more and more about people using precision drugs that align with entire genetic signatures and information to direct the treatment to enhance efficacy and reduce trial-and-error prescribing.
 

The advent of digital therapeutics and smart drug delivery is also reshaping the market and providing real-time monitoring of patient adherence. Digital therapeutics and smart drug delivery systems improve patient compliance; one only sees such compliance when monitored tightly. Chronic conditions of gastrointestinal complications are also on an upward trend due to a sedentary lifestyle and poor dietary habits that generate ongoing demand for both curative and preventive-type solutions. There will also be an increase in the development of oral and other durable formulations with the unique advantage of a patient-friendly aspect to prompt compliance by patients. Regulatory leaders are showing greater leniency with fast-tracking approvals for drugs and medical reconciliation that meet an unmet medical need in a high-burden disease state like IBD and gastrointestinal cancers.
 

Gastrointestinal Therapeutics Market Analysis

The genetic segment in the market held the largest share in 2024 propelled by emerging precision medicine trends. A greater understanding of how genetic variations affect risk, severity, and treatment response in gastrointestinal diseases has pushed researchers and pharmaceutical companies toward gene-specific therapies with genetic profiles of disease as their target.
 

This is particularly useful for chronic, complex conditions such as inflammatory bowel disease (IBD), when conventional therapies may not be effective or only work intermittently. Genetic diagnostics have advanced early disease identification in addition to disease classification, facilitating a more informed selection of drug regimens for clinicians. Genetic testing is also facilitating companion diagnostics that direct targeted therapies, resulting in improved outcomes. More hospitals and specialty clinics are utilizing genomics as a standard practice to treat GI disease engaging genetic therapeutics along the way.
 

The ulcerative colitis (UC) segment in the gastrointestinal therapeutics market generated notable revenues in 2024, driven by the overall population of people with UC cases, and more patients requiring effective and long-term strategies to manage their disease. UC is a type of inflammatory bowel disease (IBD) that primarily causes long-term inflammation in the colon and rectum and is usually characterized by relapsing and remitting flare-ups. Because the rates of diagnosis have risen due to improved awareness, more patients and healthcare providers are demanding therapeutics that focus on more than just symptom modification, but instead mucosal healing and prolonged remission.
 

The therapies currently available include corticosteroids; immunomodulators; and aminosalicylates, but biologics and more recent targeted therapies, especially anti-TNF agents, JAK inhibitors, and anti-integrins are gaining traction in terms of utilization because they have shown to be better efficacious compared to traditional therapies for people with moderate to severe disease. More patients are developing a desire for alternatives to lifelong corticosteroid use, put simply, there is a demand for new medications that are safer than previous ones.
 

New medications with promising safety profiles, such as oral small molecules and subcutaneous biologics will be making their way to some patients. There are clinical trials with novel therapies, pathways, and indications currently being tested in people with ulcerative colitis, including interleukins, sphingosine-1-phosphate, and more that are likely to increase options for patients with UC.
 

North America gastrointestinal therapeutics market held sizeable growth in 2024 driven by high prevalence of chronic gastrointestinal disorders, sizable healthcare spending, and developed regulatory and reimbursement frameworks that permit the treatment of gastrointestinal disorders. The United States is relevant to the market due to the presence of a dominant research and development ecosystem, and a leading international trend toward the adoption of new therapies, including biologics and precision therapies.  
 

The United States is increasingly diagnosing GERD, Crohn's, IBS, and colorectal cancer creating increasing demand for both OTC and prescription-based knowledge and advances in GI disorders. Globally, North America continues to be a meaningful global pharmaceutical market characterized by a number of global players, and existing public-private partnerships for GI research and advancement. Progress in diagnosis, using genetic and molecular investigation, has made individual treatment protocols for GI patients a reality.
 

Gastrointestinal Therapeutics Market Share

Notable players in the gastrointestinal therapeutics industry include:

• Pfizer
• AbbVie Inc.
• GlaxoSmithKline plc
• Bayer AG
• Allergan plc
• Takeda Pharmaceuticals
• AstraZeneca
• Janssen Pharmaceuticals
• Valeant Pharmaceuticals
• Abbott Laboratories
   

Large companies in the gastrointestinal therapeutics space are pursuing a variety of tactics to enhance their competitive position. The main tactic is an investment in R&D, specifically biologics, small molecule therapies, and gene therapies, they are also pursuing even more collaborations and licensing opportunities for drug development and market access, company mergers and acquisitions to diversify their portfolio, and potentially incorporate innovative pipeline opportunities, and the companies that used to solve patients' adherence issues, start-ups are now innovating for new drug delivery approaches such as oral extended-release drugs and subcutaneous injection.
 

Gastrointestinal Therapeutics Industry News

• In March 2025, Cadila Pharmaceuticals introduced Cadilose—an advanced Lactulose formulation aimed at effectively managing constipation and hepatic encephalopathy (HE). This launch strengthened the company’s gastrointestinal portfolio and reflected its ongoing commitment to advancing patient care and improving quality of life through pharmaceutical progress.
   
• In November 2024, Werewolf Therapeutics Inc. expanded its pipeline by adding a novel IL-10 Indukine development candidate, WTX-921, aimed at treating inflammatory bowel disease (IBD) and potentially other inflammatory conditions.